Federal Circuit Provides Insight on Induced Infringement Claims in Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc.
Briefly

from Intellectual Property Law Blog7 months ago
Hikma's application for a generic version of icosapent ethyl with a 'skinny label' led to allegations of inducement to infringe Amarin's patents on Vascepa®.
Intellectual Property Law Bloghttps://www.intellectualpropertylawblog.com/archives/federal-circuit-provides-insight-on-induced-infringement-claims-in-amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
Read at Intellectual Property Law Blog
#patent-law #fda-regulations #pharmaceutical-marketing
[
|
]